A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer.

Cancer Res Treat · 2012 · PMC3394862 · PMID 22802751

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the former study, which showed a trend toward an improved OS benefit in the combination chemotherapy group, patients received 1,660 mg/m 2 /day of oral capecitabine for 3 weeks, and 1,000 mg/m 2 gemcitabine by infusion on days 1, 8 and 15, every 4 weeks.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.